Prognostic Value of Prothrombin Fragments 1+2 for Pulmonary Embolism Incidence
Overview
To determine the possible association of prothrombin fragments 1+2 elevation with incidents of pulmonary embolism in patients with COPD exacerbation.
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
Interventions
- Other: CT pulmonary angio, blood tests
Arms, Groups and Cohorts
- COPD exacerbation
- Patients admitted to hospital with COPD exacerbation
Participating in This Clinical Trial
Inclusion Criteria
- COPD exacerbation – Able to give informed consent – Able to perform spirometry Exclusion Criteria:
- Known malignancy – Known hypercoagulable state – Receiving anticoagulant treatment – Pregnancy – Renal failure – Allergy to Iodine
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Hillel Yaffe Medical Center
- Provider of Information About this Clinical Study
- Marinella Beckerman, Hillel Yaffe Medical Center
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.